Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
David S HongKathleen M MooreJohanna C BendellDaniel D KarpJudy S WangSusanna V UlahannanSuzanne F JonesWenjuan WuGregory P DonohoYan DingAndrew CapenAimee Bence LinManish R PatelPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Prexasertib + samotolisib showed antitumor activity in preclinical models and preliminary efficacy in heavily pretreated patients. The clinical combination was associated with toxicity, suggesting supportive measures may be required. However, these data may inform future trials using other CHK1 and PI3K pathway inhibitors.